Actavis plc has confirmed that the United States District Court for the District of Delaware has found certain claims of United States Patent Nos. 6,335,031 and 6,316,023 valid and infringed by Actavis’ generic version of Novartis’ Exelon Patch (rivastigmine transdermal system).  Actavis is reviewing the court’s decision and will evaluate all available options, including an appeal, said Actavis in a press statement.

Exelon Patch is a prescription medicine used to treat people with mild to moderate dementia associated with Alzheimer’s or Parkinson’s disease.  Actavis’ abbreviated new drug application for its generic version of Exelon Patch is currently pending with the US Food and Drug Administration.

Source: Actavis